HIV/AIDS Topics New HIV PrEP Studies Will Be a Challenge, Statisticians Warn
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 17 February 2016 00:00
- Written by Gus Cairns
Two statisticians involved in the PROUD and iPrEx trials of HIV pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California at San Francisco say that statisticians will need to choose and analyze their trial populations very carefully if they wish to be able to demonstrate meaningful results.
PrEP Use Rising Among High-Risk Gay Men in Washington State
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 12 February 2016 00:00
- Written by Liz Highleyman
More than 20% of gay and bisexual men in Washington State considered to be at high risk for HIV infection were taking Truvada pre-exposure prophylaxis (PrEP) in 2015, and a large majority of both higher- and lower-risk men were aware of it, according to a study published in the January 28 edition of AIDS.
PrEP Plus Increased Testing and Treatment Could Halve HIV Infections Among UK Gay Men
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 20 January 2016 00:00
- Written by Gus Cairns
A new British mathematical modeling study published in The Lancet HIV has found that adding pre-exposure prophylaxis (PrEP) for gay men in the U.K. at high risk of HIV to relatively modest increases in HIV testing and immediate treatment for those diagnosed could substantially cut the number of gay men infected by 2020.
2 Cases of PrEP Failure on Solo Tenofovir Pose Research Questions
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 20 January 2016 00:00
- Written by Gus Cairns
A report originally presented to the 2015 British HIV Association conference last year details 2 cases where therapeutic levels of tenofovir used alone for hepatitis B treatment unequivocally failed to prevent HIV infection in gay men. In one case, despite the tenofovir apparently suppressing the man’s HIV viral load in his blood plasma, it failed to prevent HIV infecting the cells of his immune system.
Model Suggests HIV Vaccine Could Play Key Role in Ending AIDS
- Details
- Category: HIV Vaccines
- Published on Wednesday, 20 January 2016 00:00
- Written by Liz Highleyman
Even a modestly effective HIV vaccine would likely be cost-effective and could make a major contribution to a sustainable response to the global HIV/AIDS epidemic, especially in combination with the scale-up of other interventions including prompt antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), according to a report in the January 5 edition of PLoS ONE.
Web Design and Development by